Collegium Pharmaceutical to acquire AZSTARYS franchise for $650 million

The deal, funded with cash and debt, marks a shift from pain management toward a broader central nervous system platform through an ADHD franchise acquisition.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.